https://trial.medpath.com/news/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/news/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gohibic-for-sars-cov-2-induced-ards-among-eight-new-drugs-to-win-ema-nod 2024-11-15T23:36:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gohibic-for-sars-cov-2-induced-ards-among-eight-new-drugs-to-win-ema-nod 2024-11-15T23:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/pearl-study-compares-first-line-durvalumab-monotherapy-with-chemotherapy-in 2024-11-15T23:27:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pearl-study-compares-first-line-durvalumab-monotherapy-with-chemotherapy-in 2024-11-15T23:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-menin-inhibitor-for-acute-leukemia-medpage-today 2024-11-15T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-menin-inhibitor-for-acute-leukemia-medpage-today 2024-11-15T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-markets-data 2024-11-15T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-markets-data 2024-11-15T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-morningstar 2024-11-15T22:48:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-morningstar 2024-11-15T22:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-s-revuforj-wins-fda-approval-as-first-menin-inhibitor-for-acute-leukemia-sndx 2024-11-15T22:45:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-s-revuforj-wins-fda-approval-as-first-menin-inhibitor-for-acute-leukemia-sndx 2024-11-15T22:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-strong-financials-strategic-fda-approval-and-growth-prospects-drive 2024-11-15T22:41:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-therapeutics-strong-financials-strategic-fda-approval-and-growth-prospects-drive 2024-11-15T22:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-15T22:39:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-15T22:39:49+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-placera 2024-11-15T22:31:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-placera 2024-11-15T22:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-cognition-s-fda-approved-alzheimer-s-drug-zunveyl-set-for-2025-launch 2024-11-15T22:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-cognition-s-fda-approved-alzheimer-s-drug-zunveyl-set-for-2025-launch 2024-11-15T22:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-completes-4m-ipo-for-skin-cancer-treatment-development-mdcx-stock-news 2024-11-15T21:55:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-completes-4m-ipo-for-skin-cancer-treatment-development-mdcx-stock-news 2024-11-15T21:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T21:53:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T21:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemia 2024-11-15T21:50:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemia 2024-11-15T21:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revuforj-for-relapsed-refractory-acute-leukemia-subset-cure-today 2024-11-15T21:44:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revuforj-for-relapsed-refractory-acute-leukemia-subset-cure-today 2024-11-15T21:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-no-birth-defect-risk-from-tetracycline-use-during-first-trimester-of-pregnancy 2024-11-15T21:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-no-birth-defect-risk-from-tetracycline-use-during-first-trimester-of-pregnancy 2024-11-15T21:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-relapsed-refractory-kmt2a-translocated-acute-leukemia 2024-11-15T21:35:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-for-relapsed-refractory-kmt2a-translocated-acute-leukemia 2024-11-15T21:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation-onclive 2024-11-15T21:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation-onclive 2024-11-15T21:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/positive-ema-reversal-boosts-biogen-s-leqembi-prospects-despite-challenges 2024-11-15T21:27:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-ema-reversal-boosts-biogen-s-leqembi-prospects-despite-challenges 2024-11-15T21:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-aadc-deficiency-treatment-scientist-live 2024-11-15T21:22:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-aadc-deficiency-treatment-scientist-live 2024-11-15T21:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-wins-on-appeal-chmp-recommends-leqembi-for-alzheimer-s-bioworld 2024-11-15T20:50:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-wins-on-appeal-chmp-recommends-leqembi-for-alzheimer-s-bioworld 2024-11-15T20:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/filament-health-revenue-slides-94-as-cash-reserves-dwindle-green-market-report 2024-11-15T20:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/filament-health-revenue-slides-94-as-cash-reserves-dwindle-green-market-report 2024-11-15T20:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/european-agency-signals-approval-for-keytruda-for-first-line-mesothelioma-treatment 2024-11-15T20:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-agency-signals-approval-for-keytruda-for-first-line-mesothelioma-treatment 2024-11-15T20:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/the-joy-of-witnessing-science-transform-a-life-research-horizons 2024-11-15T20:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-joy-of-witnessing-science-transform-a-life-research-horizons 2024-11-15T20:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-ninlotinib-tablets-with-no-mealtime-restrictions-for-cml-oncology-nursing-news 2024-11-15T20:10:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-ninlotinib-tablets-with-no-mealtime-restrictions-for-cml-oncology-nursing-news 2024-11-15T20:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/outcomes-of-contemporary-therapy-for-cardiogenic-shock-due-to-severe-aortic-stenosis 2024-11-15T20:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outcomes-of-contemporary-therapy-for-cardiogenic-shock-due-to-severe-aortic-stenosis 2024-11-15T20:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/repotrectinib-garners-positive-chmp-opinion-for-ros1-nsclc-and-ntrk-solid-tumors 2024-11-15T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repotrectinib-garners-positive-chmp-opinion-for-ros1-nsclc-and-ntrk-solid-tumors 2024-11-15T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy 2024-11-15T20:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy 2024-11-15T20:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-sbla-review-for-dupilumab-in-treatment-of-csu-in-adult-and-pediatric-patients 2024-11-15T19:59:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-sbla-review-for-dupilumab-in-treatment-of-csu-in-adult-and-pediatric-patients 2024-11-15T19:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/nerivio-ren-wearable-now-fda-cleared-to-treat-migraines-in-children-8-years-and-up 2024-11-15T19:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nerivio-ren-wearable-now-fda-cleared-to-treat-migraines-in-children-8-years-and-up 2024-11-15T19:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nilotinib-with-no-mealtime-restrictions-in-ph-positive-cml 2024-11-15T19:42:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nilotinib-with-no-mealtime-restrictions-in-ph-positive-cml 2024-11-15T19:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-ag-de000a1ewvy8-ad-hoc-news-de 2024-11-15T19:37:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/formycon-ag-de000a1ewvy8-ad-hoc-news-de 2024-11-15T19:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/plx-self-sustaining-rise-to-lead-in-renal-rare-disease-zacks-small-cap-research 2024-11-15T19:30:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plx-self-sustaining-rise-to-lead-in-renal-rare-disease-zacks-small-cap-research 2024-11-15T19:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-reports-third-quarter-2024-financial-results-yahoo-finance 2024-11-15T19:21:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-reports-third-quarter-2024-financial-results-yahoo-finance 2024-11-15T19:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/with-phase-iii-myopia-termination-eyenovia-open-to-all-strategic-options-citeline 2024-11-15T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-phase-iii-myopia-termination-eyenovia-open-to-all-strategic-options-citeline 2024-11-15T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/tamil-nadu-launches-phase-ii-of-uttasathai-uruthi-sei-scheme-to-support-pregnant-women 2024-11-15T19:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tamil-nadu-launches-phase-ii-of-uttasathai-uruthi-sei-scheme-to-support-pregnant-women 2024-11-15T19:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-european-commission-approval-for-afqlir-r-aflibercept-further-biospace 2024-11-15T19:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-receives-european-commission-approval-for-afqlir-r-aflibercept-further-biospace 2024-11-15T19:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-biospace 2024-11-15T19:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-biospace 2024-11-15T19:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/granite-plus-icis-and-bevacizumab-chemo-shows-improved-pfs-trend-in-mss-mcrc 2024-11-15T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/granite-plus-icis-and-bevacizumab-chemo-shows-improved-pfs-trend-in-mss-mcrc 2024-11-15T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/nmo-drug-looks-good-for-igg4-related-disease-medpage-today 2024-11-15T19:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmo-drug-looks-good-for-igg4-related-disease-medpage-today 2024-11-15T19:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday-benzinga 2024-11-15T18:47:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday-benzinga 2024-11-15T18:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday 2024-11-15T18:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday 2024-11-15T18:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-reverses-opinion-on-lecanemab-for-alzheimer-disease-but 2024-11-15T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-reverses-opinion-on-lecanemab-for-alzheimer-disease-but 2024-11-15T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmission-of-supplemental-biologics-license-application-for-dupixent-for 2024-11-15T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-resubmission-of-supplemental-biologics-license-application-for-dupixent-for 2024-11-15T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-testing-beta-blocker-celiprolol-for-veds-in-phase-3-us-study-ehlers-danlos-news 2024-11-15T18:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-testing-beta-blocker-celiprolol-for-veds-in-phase-3-us-study-ehlers-danlos-news 2024-11-15T18:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/anda-approvals-new-drug-applications-and-505-b-2-applications-third-quarter 2024-11-15T18:35:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anda-approvals-new-drug-applications-and-505-b-2-applications-third-quarter 2024-11-15T18:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-15T18:32:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-15T18:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/how-a-biogen-drug-set-the-stage-for-a-new-biotech-targeting-als-biopharma-dive 2024-11-15T18:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-a-biogen-drug-set-the-stage-for-a-new-biotech-targeting-als-biopharma-dive 2024-11-15T18:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-class-of-hemophilia-treatment-coagulation-disorders-jama-network 2024-11-15T18:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-class-of-hemophilia-treatment-coagulation-disorders-jama-network 2024-11-15T18:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-attractive-targeted-sugar-bait-stations-against-malaria-in-western-province-zambia 2024-11-15T18:20:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-attractive-targeted-sugar-bait-stations-against-malaria-in-western-province-zambia 2024-11-15T18:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-s-car-t-allo-316-demonstrates-ability-to-produce-responses-in-renal-cell 2024-11-15T18:18:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogene-s-car-t-allo-316-demonstrates-ability-to-produce-responses-in-renal-cell 2024-11-15T18:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T18:15:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T18:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/study-launches-of-qxl138am-in-multiple-myeloma-and-solid-tumors-targeted-oncology 2024-11-15T18:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-launches-of-qxl138am-in-multiple-myeloma-and-solid-tumors-targeted-oncology 2024-11-15T18:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-danziten-for-leukemia-subset-that-does-not-require-fasting-cure-today 2024-11-15T18:04:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-danziten-for-leukemia-subset-that-does-not-require-fasting-cure-today 2024-11-15T18:04:48+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-receives-european-commission-approval-for-afqlir-r-globenewswire 2024-11-15T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-receives-european-commission-approval-for-afqlir-r-globenewswire 2024-11-15T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-reviews-sanofi-and-regeneron-s-dupixent-label-expansion-for-urticaria 2024-11-15T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-reviews-sanofi-and-regeneron-s-dupixent-label-expansion-for-urticaria 2024-11-15T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-15T17:37:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-15T17:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/why-the-ema-said-no-to-kizfizo-and-cinainu 2024-11-15T17:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-the-ema-said-no-to-kizfizo-and-cinainu 2024-11-15T17:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/two-year-phase-iii-data-confirm-long-term-efficacy-safety-of-bimzelx-in-psoriatic-arthritis 2024-11-15T17:28:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-year-phase-iii-data-confirm-long-term-efficacy-safety-of-bimzelx-in-psoriatic-arthritis 2024-11-15T17:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-inc-announces-positive-end-of-t-treatment-results-for-tobevibart-and 2024-11-15T17:25:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-inc-announces-positive-end-of-t-treatment-results-for-tobevibart-and 2024-11-15T17:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-marketing-authorization-to-biosimilar-from-sandoz-group 2024-11-15T17:24:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-marketing-authorization-to-biosimilar-from-sandoz-group 2024-11-15T17:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T17:24:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T17:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/positive-chmp-opinion-for-formycon-s-aflibercept-biosimilar-fyb203-webdisclosure 2024-11-15T17:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-chmp-opinion-for-formycon-s-aflibercept-biosimilar-fyb203-webdisclosure 2024-11-15T17:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-plus-vrd-earns-chmp-recommendation-for-newly-diagnosed-transplant 2024-11-15T17:12:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isatuximab-plus-vrd-earns-chmp-recommendation-for-newly-diagnosed-transplant 2024-11-15T17:12:17+00:00 weekly 0.7 https://trial.medpath.com/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:09:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-l-amino-acid-decarboxylase-deficiency-gene-therapy-nature 2024-11-15T17:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-l-amino-acid-decarboxylase-deficiency-gene-therapy-nature 2024-11-15T17:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-chemo-earns-positive-eu-chmp-opinion-in-mesothelioma 2024-11-15T17:07:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-chemo-earns-positive-eu-chmp-opinion-in-mesothelioma 2024-11-15T17:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-macau-business 2024-11-15T17:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-watchdog-partially-approves-new-alzheimer-s-drug-macau-business 2024-11-15T17:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-chemoradiation-followed-by-immunochemotherapy-and-surgery-may-improve 2024-11-15T17:02:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-chemoradiation-followed-by-immunochemotherapy-and-surgery-may-improve 2024-11-15T17:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/drugs-like-ozempic-may-help-lower-2nd-stroke-heart-attack-risk 2024-11-15T17:02:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drugs-like-ozempic-may-help-lower-2nd-stroke-heart-attack-risk 2024-11-15T17:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-15T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-15T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-four-approvals-and-10-phase-iii-readouts-citeline 2024-11-15T16:56:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-watch-four-approvals-and-10-phase-iii-readouts-citeline 2024-11-15T16:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-combination-for-cutaneous-melanoma-the-asco-post 2024-11-15T16:54:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-combination-for-cutaneous-melanoma-the-asco-post 2024-11-15T16:54:52+00:00 weekly 0.7 https://trial.medpath.com/news/ac-immune-s-stock-jumps-after-parkinson-s-therapy-shows-signs-of-benefit 2024-11-15T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ac-immune-s-stock-jumps-after-parkinson-s-therapy-shows-signs-of-benefit 2024-11-15T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-hits-enrolment-target-for-vagus-nerve-stimulation-trial 2024-11-15T16:51:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivic-hits-enrolment-target-for-vagus-nerve-stimulation-trial 2024-11-15T16:51:37+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-nivolumab-ipilimumab-in-msi-h-dmmr-mcrc-onclive 2024-11-15T16:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-nivolumab-ipilimumab-in-msi-h-dmmr-mcrc-onclive 2024-11-15T16:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/an-update-on-therapeutics-for-covid-19-medpage-today 2024-11-15T16:47:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-update-on-therapeutics-for-covid-19-medpage-today 2024-11-15T16:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/research-study-explores-targeted-therapy-for-recurrent-high-grade-glioma 2024-11-15T16:36:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-study-explores-targeted-therapy-for-recurrent-high-grade-glioma 2024-11-15T16:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-application-for-dupilumab-to-treat-chronic-spontaneous-urticaria 2024-11-15T16:31:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-application-for-dupilumab-to-treat-chronic-spontaneous-urticaria 2024-11-15T16:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-new-nilotinib-formulation-approval-to-treat-adults-with-chronic-myeloid-leukemia 2024-11-15T16:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-new-nilotinib-formulation-approval-to-treat-adults-with-chronic-myeloid-leukemia 2024-11-15T16:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-gets-positive-ema-opinion-for-repotrectinib-nyse-bmy-seeking-alpha 2024-11-15T16:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-gets-positive-ema-opinion-for-repotrectinib-nyse-bmy-seeking-alpha 2024-11-15T16:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gene-therapy-kebilidi-to-treat-aadc-deficiency-receives-us-fda-approval 2024-11-15T16:28:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-gene-therapy-kebilidi-to-treat-aadc-deficiency-receives-us-fda-approval 2024-11-15T16:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-therapeutics-kebillidi-for-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-15T16:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ptc-therapeutics-kebillidi-for-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-15T16:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/vir-bio-s-hepatitis-b-treatment-shows-46-success-rate-in-key-clinical-trial-stock-titan 2024-11-15T16:25:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-bio-s-hepatitis-b-treatment-shows-46-success-rate-in-key-clinical-trial-stock-titan 2024-11-15T16:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-15T16:25:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-15T16:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-shares-plummet-70-after-it-drops-lead-program-biospace 2024-11-15T16:22:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-shares-plummet-70-after-it-drops-lead-program-biospace 2024-11-15T16:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-markets-data 2024-11-15T16:21:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-markets-data 2024-11-15T16:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/promising-hepatitis-b-treatment-data-presented-by-vir-biotechnology-investing-com 2024-11-15T16:19:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-hepatitis-b-treatment-data-presented-by-vir-biotechnology-investing-com 2024-11-15T16:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-immunotherapy-aci-7104-056-demonstrates-positive-antibody-responses-in 2024-11-15T16:09:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-immunotherapy-aci-7104-056-demonstrates-positive-antibody-responses-in 2024-11-15T16:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-the-nhs-digitrials 2024-11-15T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-the-nhs-digitrials 2024-11-15T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/barinthus-bio-announces-results-from-ongoing-phase-2b-globenewswire 2024-11-15T16:07:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/barinthus-bio-announces-results-from-ongoing-phase-2b-globenewswire 2024-11-15T16:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-designation-to-elraglusib-for-ewing-sarcoma-oncology-nursing-news 2024-11-15T16:05:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-designation-to-elraglusib-for-ewing-sarcoma-oncology-nursing-news 2024-11-15T16:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/in-brief-rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-shares-magazine 2024-11-15T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-brief-rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-shares-magazine 2024-11-15T16:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/first-clinical-trial-of-memory-like-natural-killer-cells-in-ovarian-cancer-opens-at-dana-farber 2024-11-15T15:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-clinical-trial-of-memory-like-natural-killer-cells-in-ovarian-cancer-opens-at-dana-farber 2024-11-15T15:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment 2024-11-15T15:33:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment 2024-11-15T15:33:15+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-rybrevant-r-amivantamab-in-combination-globenewswire 2024-11-15T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-rybrevant-r-amivantamab-in-combination-globenewswire 2024-11-15T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-ultrasound-guided-individualized-positive-end-expiratory-pressure-on-the-severity-of 2024-11-15T15:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-ultrasound-guided-individualized-positive-end-expiratory-pressure-on-the-severity-of 2024-11-15T15:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/how-to-accelerate-glycolysis-and-treat-parkinson-s-disease-drug-discovery-news 2024-11-15T15:24:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-to-accelerate-glycolysis-and-treat-parkinson-s-disease-drug-discovery-news 2024-11-15T15:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/delandistrogene-moxeparvovec-fails-to-meet-primary-endpoint-in-phase-3-study 2024-11-15T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delandistrogene-moxeparvovec-fails-to-meet-primary-endpoint-in-phase-3-study 2024-11-15T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/application-for-rtw-biotech-opportunities-corxel-s-aficamten-accepted-by-chinese-regulator 2024-11-15T15:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/application-for-rtw-biotech-opportunities-corxel-s-aficamten-accepted-by-chinese-regulator 2024-11-15T15:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-15T15:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-15T15:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ind-for-as1986ns-a-new-approach-in-prostate-cancer-research 2024-11-15T15:05:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ind-for-as1986ns-a-new-approach-in-prostate-cancer-research 2024-11-15T15:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/foresee-pharmaceuticals-receives-the-second-positive-recommendation-from-dsmb-to 2024-11-15T15:03:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-receives-the-second-positive-recommendation-from-dsmb-to 2024-11-15T15:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/drug-combination-boosts-immune-response-in-resistant-pancreatic-cancers 2024-11-15T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-combination-boosts-immune-response-in-resistant-pancreatic-cancers 2024-11-15T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sets-date-for-resubmitted-dupixent-in-inflammatory-skin-disease-formulary-watch 2024-11-15T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-sets-date-for-resubmitted-dupixent-in-inflammatory-skin-disease-formulary-watch 2024-11-15T15:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-for 2024-11-15T14:56:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-for 2024-11-15T14:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-sequencing-and-treatment-options-in-the-tumor-agnostic-setting-cancer-network 2024-11-15T14:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-sequencing-and-treatment-options-in-the-tumor-agnostic-setting-cancer-network 2024-11-15T14:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-completes-phase-2b-trial-dosing-awaits-key-december-data-ostx-stock-news 2024-11-15T14:54:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-completes-phase-2b-trial-dosing-awaits-key-december-data-ostx-stock-news 2024-11-15T14:54:09+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T14:54:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T14:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-veliparib-to-temozolomide-in-newly-diagnosed-mgmt-methylated-glioblastoma 2024-11-15T14:45:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-veliparib-to-temozolomide-in-newly-diagnosed-mgmt-methylated-glioblastoma 2024-11-15T14:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-strategy-reverses-resistance-to-immunotherapy-in-pancreatic-cancer 2024-11-15T14:39:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-strategy-reverses-resistance-to-immunotherapy-in-pancreatic-cancer 2024-11-15T14:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-showcases-early-cancer-detection-test-data-at-aacr-meeting 2024-11-15T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-showcases-early-cancer-detection-test-data-at-aacr-meeting 2024-11-15T14:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-holding-company-announces-presentation-of-data-at-the-2024-american-college-of 2024-11-15T14:24:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-holding-company-announces-presentation-of-data-at-the-2024-american-college-of 2024-11-15T14:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-s-gloperba-r-showcases-breakthrough-kidney-disease-dosing-data-at-acr-conference 2024-11-15T14:15:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-s-gloperba-r-showcases-breakthrough-kidney-disease-dosing-data-at-acr-conference 2024-11-15T14:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/cero-therapeutics-secures-fda-clearance-for-novel-aml-treatment-clinical-trial 2024-11-15T14:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cero-therapeutics-secures-fda-clearance-for-novel-aml-treatment-clinical-trial 2024-11-15T14:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/rwanda-steps-up-measures-against-rift-valley-fever-gavi-the-vaccine-alliance 2024-11-15T14:08:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rwanda-steps-up-measures-against-rift-valley-fever-gavi-the-vaccine-alliance 2024-11-15T14:08:51+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-research-promises-shorter-treatment-for-multi-drug-resistant-tb 2024-11-15T13:56:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-research-promises-shorter-treatment-for-multi-drug-resistant-tb 2024-11-15T13:56:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-decision-on-abeona-s-pz-cel-for-rdeb-now-expected-by-april-29 2024-11-15T13:55:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-decision-on-abeona-s-pz-cel-for-rdeb-now-expected-by-april-29 2024-11-15T13:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-halts-enrollment-in-leukemia-trial-by-investing-com 2024-11-15T13:54:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogene-halts-enrollment-in-leukemia-trial-by-investing-com 2024-11-15T13:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-receives-positive-chmp-opinion-for-globenewswire 2024-11-15T13:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-receives-positive-chmp-opinion-for-globenewswire 2024-11-15T13:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/cero-therapeutics-inc-receives-fda-clearance-of-globenewswire 2024-11-15T13:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cero-therapeutics-inc-receives-fda-clearance-of-globenewswire 2024-11-15T13:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-first-brain-delivered-gene-therapy-for-rare-aadc-disease 2024-11-15T13:44:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kebilidi-first-brain-delivered-gene-therapy-for-rare-aadc-disease 2024-11-15T13:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-gets-ema-nod-for-covid-19-treatment-tipranks-com 2024-11-15T13:38:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-gets-ema-nod-for-covid-19-treatment-tipranks-com 2024-11-15T13:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/sbrt-is-feasible-for-localized-prostate-cancer-oncology-nursing-news 2024-11-15T13:38:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sbrt-is-feasible-for-localized-prostate-cancer-oncology-nursing-news 2024-11-15T13:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-nasdaq-pdsb-q3-2024-earnings-call-transcript 2024-11-15T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corporation-nasdaq-pdsb-q3-2024-earnings-call-transcript 2024-11-15T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-pushes-nv-387-to-phase-ii-trials-nyse-a-nnvc-proactive-investors 2024-11-15T13:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-pushes-nv-387-to-phase-ii-trials-nyse-a-nnvc-proactive-investors 2024-11-15T13:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-reactions-follow-rfk-jr-s-nomination-as-hhs-secretary-raising-public-health-concerns 2024-11-15T13:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-reactions-follow-rfk-jr-s-nomination-as-hhs-secretary-raising-public-health-concerns 2024-11-15T13:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/from-the-bench-fall-2024-massachusetts-general-hospital 2024-11-15T13:20:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/from-the-bench-fall-2024-massachusetts-general-hospital 2024-11-15T13:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/selenium-proteins-breakthrough-in-cancer-research-mirage-news 2024-11-15T13:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selenium-proteins-breakthrough-in-cancer-research-mirage-news 2024-11-15T13:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/genomadix-inc-enters-into-collaboration-with-mayo-clinic-on-precision-medicine-for-telestroke 2024-11-15T13:05:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomadix-inc-enters-into-collaboration-with-mayo-clinic-on-precision-medicine-for-telestroke 2024-11-15T13:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-s-gohibic-gets-ema-panel-nod-for-covid-19-ards-by-investing-com 2024-11-15T12:59:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-s-gohibic-gets-ema-panel-nod-for-covid-19-ards-by-investing-com 2024-11-15T12:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-globenewswire 2024-11-15T12:56:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-globenewswire 2024-11-15T12:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/leveraging-genetic-variations-for-more-effective-cancer-therapies-news-medical 2024-11-15T12:53:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leveraging-genetic-variations-for-more-effective-cancer-therapies-news-medical 2024-11-15T12:53:20+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T12:52:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-receives-positive-chmp-opinion-for-gohibic-r-vilobelimab-for-the-treatment-of 2024-11-15T12:52:23+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-11-14 2024-11-15T12:46:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-11-14 2024-11-15T12:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/triglyceride-lowering-therapies-in-hypertriglyceridemia-associated-acute-pancreatitis-in-china 2024-11-15T12:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triglyceride-lowering-therapies-in-hypertriglyceridemia-associated-acute-pancreatitis-in-china 2024-11-15T12:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/shingles-vaccination-shows-dual-benefit-virus-prevention-and-cardiovascular-protection 2024-11-15T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shingles-vaccination-shows-dual-benefit-virus-prevention-and-cardiovascular-protection 2024-11-15T12:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-stock-titan 2024-11-15T12:15:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-provides-update-on-phase-3-chaperone-study-stock-titan 2024-11-15T12:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/eyenovia-provides-update-on-phase-3-chaperone-study-globenewswire 2024-11-15T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyenovia-provides-update-on-phase-3-chaperone-study-globenewswire 2024-11-15T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T12:06:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-15T12:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-globenewswire 2024-11-15T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-globenewswire 2024-11-15T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-nipocalimab-shows-promise-in-phase-ii-sjogren-s-disease-trial-clinical-trials-arena 2024-11-15T11:59:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-nipocalimab-shows-promise-in-phase-ii-sjogren-s-disease-trial-clinical-trials-arena 2024-11-15T11:59:26+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-tipranks-com 2024-11-15T11:56:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reports-promising-phase-ii-sarcoma-trial-results-tipranks-com 2024-11-15T11:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-antiviral-drug-nv-387-advances-to-phase-ii-trials-amid-funding-needs 2024-11-15T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-antiviral-drug-nv-387-advances-to-phase-ii-trials-amid-funding-needs 2024-11-15T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-advances-nv-387-to-phase-ii-trials-for-multiple-viral-infections 2024-11-15T11:45:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-advances-nv-387-to-phase-ii-trials-for-multiple-viral-infections 2024-11-15T11:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-to-review-sanofi-regeneron-s-dupixent-sbla-for-csu 2024-11-15T11:40:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-to-review-sanofi-regeneron-s-dupixent-sbla-for-csu 2024-11-15T11:40:58+00:00 weekly 0.7 https://trial.medpath.com/news/more-evidence-that-glp-1-meds-curb-alcohol-abuse 2024-11-15T11:03:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-evidence-that-glp-1-meds-curb-alcohol-abuse 2024-11-15T11:03:32+00:00 weekly 0.7 https://trial.medpath.com/news/chlamydia-vaccine-shows-early-promise-in-mice 2024-11-15T11:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chlamydia-vaccine-shows-early-promise-in-mice 2024-11-15T11:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/mymelanoma-study-selected-to-join-new-nhs-digitrials-initiative-oxford-cancer 2024-11-15T10:46:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mymelanoma-study-selected-to-join-new-nhs-digitrials-initiative-oxford-cancer 2024-11-15T10:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/could-weight-loss-drugs-fix-uk-s-unemployment-problem-al-jazeera 2024-11-15T10:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-weight-loss-drugs-fix-uk-s-unemployment-problem-al-jazeera 2024-11-15T10:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/combination-treatment-for-esophageal-cancer-the-aacr 2024-11-15T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-treatment-for-esophageal-cancer-the-aacr 2024-11-15T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for 2024-11-15T10:22:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for 2024-11-15T10:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-positive-outcomes-from-phase-iii-multiple-myeloma-treatment-trial 2024-11-15T10:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-positive-outcomes-from-phase-iii-multiple-myeloma-treatment-trial 2024-11-15T10:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-marketscreener 2024-11-15T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-marketscreener 2024-11-15T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-a-new-nhs-digitrials 2024-11-15T10:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-a-new-nhs-digitrials 2024-11-15T10:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-discovery-enables-use-for-muscular-dystrophies-and-large-gene-diseases 2024-11-15T10:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-discovery-enables-use-for-muscular-dystrophies-and-large-gene-diseases 2024-11-15T10:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/finally-therapeutic-antibodies-start-to-reduce-tangles-alzforum 2024-11-15T09:52:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/finally-therapeutic-antibodies-start-to-reduce-tangles-alzforum 2024-11-15T09:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/caamtech-s-psychedelic-functional-unblinding-strategy-gets-regulatory-blessing 2024-11-15T09:27:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caamtech-s-psychedelic-functional-unblinding-strategy-gets-regulatory-blessing 2024-11-15T09:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-recommends-sanofi-s-sarclisa-approval-for-multiple-myeloma 2024-11-15T09:23:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-sanofi-s-sarclisa-approval-for-multiple-myeloma 2024-11-15T09:23:26+00:00 weekly 0.7 https://trial.medpath.com/news/adding-immunotherapy-to-neoadjuvant-chemoradiation-may-improve-outcomes-in 2024-11-15T09:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-immunotherapy-to-neoadjuvant-chemoradiation-may-improve-outcomes-in 2024-11-15T09:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/q1-interim-report-july-2024-september-2024-hamlet-biopharma-ab-publ 2024-11-15T08:48:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q1-interim-report-july-2024-september-2024-hamlet-biopharma-ab-publ 2024-11-15T08:48:20+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:46:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:46:47+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:43:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-15T08:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-lasting-impact-of-the-cross-trial-on-gej-cancer-care-targeted-oncology 2024-11-15T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-lasting-impact-of-the-cross-trial-on-gej-cancer-care-targeted-oncology 2024-11-15T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/99-of-mounjaro-zepbound-patients-remained-diabetes-free-even-at-3-years-eli-lilly-s 2024-11-15T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/99-of-mounjaro-zepbound-patients-remained-diabetes-free-even-at-3-years-eli-lilly-s 2024-11-15T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-announces-fda-approval-for-phase-1-trial-of-rhenium-186re-barchart-com 2024-11-15T07:44:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plus-therapeutics-announces-fda-approval-for-phase-1-trial-of-rhenium-186re-barchart-com 2024-11-15T07:44:07+00:00 weekly 0.7 https://trial.medpath.com/news/a-study-within-a-trial-swat-of-clinical-trial-feasibility-and-barriers-to-recruitment-in-the 2024-11-15T07:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-study-within-a-trial-swat-of-clinical-trial-feasibility-and-barriers-to-recruitment-in-the 2024-11-15T07:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/ema-gives-partial-go-ahead-for-first-alzheimer-s-treatment-in-eu-belganewsagency-eu 2024-11-15T07:39:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-gives-partial-go-ahead-for-first-alzheimer-s-treatment-in-eu-belganewsagency-eu 2024-11-15T07:39:12+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corp-pdsb-q3-2024-earnings-call-highlights-navigating-financial 2024-11-15T07:21:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corp-pdsb-q3-2024-earnings-call-highlights-navigating-financial 2024-11-15T07:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:56:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:54:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic 2024-11-15T06:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ptc-s-kebilidi-as-first-gene-therapy-to-treat-aadc-deficiency-rttnews 2024-11-15T06:15:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ptc-s-kebilidi-as-first-gene-therapy-to-treat-aadc-deficiency-rttnews 2024-11-15T06:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-15T06:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-15T06:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/select-mds-1-trial-of-tamibarotene-misses-primary-end-point-in-mds 2024-11-15T06:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/select-mds-1-trial-of-tamibarotene-misses-primary-end-point-in-mds 2024-11-15T06:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/balancing-clinical-data-and-real-world-insights-in-cml-treatment-targeted-oncology 2024-11-15T06:14:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/balancing-clinical-data-and-real-world-insights-in-cml-treatment-targeted-oncology 2024-11-15T06:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/sandoz-wins-eu-approval-for-eylea-biosimilar-to-treat-vision-loss-launch-set-for-2025 2024-11-15T06:03:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sandoz-wins-eu-approval-for-eylea-biosimilar-to-treat-vision-loss-launch-set-for-2025 2024-11-15T06:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-sbla-accepted-for-fda-review-for-globenewswire 2024-11-15T06:03:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-sbla-accepted-for-fda-review-for-globenewswire 2024-11-15T06:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-glp-1-prescriptions-surge-sevenfold-as-experts-navigate-benefits-and-risks 2024-11-15T05:50:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pediatric-glp-1-prescriptions-surge-sevenfold-as-experts-navigate-benefits-and-risks 2024-11-15T05:50:23+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating 2024-11-15T05:34:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-inc-strategic-advancements-and-financial-robustness-drive-buy-rating 2024-11-15T05:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-results-from-head-to-head-dreamm-7-phase-iii-trial-of-blenrep-in 2024-11-15T05:29:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-results-from-head-to-head-dreamm-7-phase-iii-trial-of-blenrep-in 2024-11-15T05:29:31+00:00 weekly 0.7 https://trial.medpath.com/news/q3-2024-biomx-inc-earnings-call-yahoo-finance 2024-11-15T05:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q3-2024-biomx-inc-earnings-call-yahoo-finance 2024-11-15T05:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-gets-us-fda-approval-for-brain-delivered-gene-therapy-citeline 2024-11-15T05:05:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-gets-us-fda-approval-for-brain-delivered-gene-therapy-citeline 2024-11-15T05:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/patient-centric-trial-design-key-strategies-for-improving-clinical-research-success 2024-11-15T05:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-centric-trial-design-key-strategies-for-improving-clinical-research-success 2024-11-15T05:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/elutia-inc-reports-strong-q3-results-prepares-for-major-product-launch-tipranks-com 2024-11-15T05:00:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elutia-inc-reports-strong-q3-results-prepares-for-major-product-launch-tipranks-com 2024-11-15T05:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/eu-regulator-backs-eisai-biogen-alzheimer-s-drug-the-hindu 2024-11-15T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-regulator-backs-eisai-biogen-alzheimer-s-drug-the-hindu 2024-11-15T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-l-carnitine-supplementation-on-gastric-emptying-and-bowel-function-in-pediatric 2024-11-15T04:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-l-carnitine-supplementation-on-gastric-emptying-and-bowel-function-in-pediatric 2024-11-15T04:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/munich-to-host-clinical-trials-in-oncology-europe-2024-ai-strategy-and-patient-experience-take-center-stage 2024-11-15T04:11:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/munich-to-host-clinical-trials-in-oncology-europe-2024-ai-strategy-and-patient-experience-take-center-stage 2024-11-15T04:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-placera 2024-11-15T04:06:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-placera 2024-11-15T04:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-lays-off-45-of-employees-biospace 2024-11-15T04:06:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-lays-off-45-of-employees-biospace 2024-11-15T04:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-present-updated-os-analysis-of-perla-trial-in-metastatic-nsclc 2024-11-15T04:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-present-updated-os-analysis-of-perla-trial-in-metastatic-nsclc 2024-11-15T04:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/tivic-completes-enrollment-in-nerve-stim-trial-massdevice 2024-11-15T04:04:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivic-completes-enrollment-in-nerve-stim-trial-massdevice 2024-11-15T04:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/angiotensin-ii-and-thromboembolism-reading-the-fine-print-critical-care-medicine 2024-11-15T04:04:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angiotensin-ii-and-thromboembolism-reading-the-fine-print-critical-care-medicine 2024-11-15T04:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-leaders-share-three-critical-strategies-for-r-d-success-in-drug-development 2024-11-15T04:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-leaders-share-three-critical-strategies-for-r-d-success-in-drug-development 2024-11-15T04:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-brain-delivered-gene-therapy-approved-for-aadc-deficiency-medpage-today 2024-11-15T03:57:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-brain-delivered-gene-therapy-approved-for-aadc-deficiency-medpage-today 2024-11-15T03:57:37+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-reports-deeper-losses-as-dmt-clinical-trial-costs-mount 2024-11-15T03:41:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gh-research-reports-deeper-losses-as-dmt-clinical-trial-costs-mount 2024-11-15T03:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/delgocitinib-approved-for-adults-with-moderate-to-severe-che-in-switzerland 2024-11-15T03:35:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delgocitinib-approved-for-adults-with-moderate-to-severe-che-in-switzerland 2024-11-15T03:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-device-garners-fda-de-novo-nod-for-kidney-stone-clearance 2024-11-15T03:29:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultrasound-device-garners-fda-de-novo-nod-for-kidney-stone-clearance 2024-11-15T03:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-seeks-fda-approval-for-sleep-enhancing-drug-for-fibromyalgia 2024-11-15T03:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-seeks-fda-approval-for-sleep-enhancing-drug-for-fibromyalgia 2024-11-15T03:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tool-sees-cancer-gene-signatures-in-biopsy-images-news-center-stanford-medicine 2024-11-15T03:00:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tool-sees-cancer-gene-signatures-in-biopsy-images-news-center-stanford-medicine 2024-11-15T03:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-finds-inebilizumab-effective-for-immunoglobulin-g4-related-disease 2024-11-15T02:40:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-study-finds-inebilizumab-effective-for-immunoglobulin-g4-related-disease 2024-11-15T02:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/allogene-shares-target-cut-rating-held-on-trial-enrollment-issue-investing-com 2024-11-15T02:11:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allogene-shares-target-cut-rating-held-on-trial-enrollment-issue-investing-com 2024-11-15T02:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-secures-ema-thumbs-up-for-narrower-indication-citeline 2024-11-15T01:49:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqembi-secures-ema-thumbs-up-for-narrower-indication-citeline 2024-11-15T01:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-price-target-lowered-to-4-50-from-7-at-alliance-global-partners 2024-11-15T01:33:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-price-target-lowered-to-4-50-from-7-at-alliance-global-partners 2024-11-15T01:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-pr-newswire 2024-11-15T01:16:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-pr-newswire 2024-11-15T01:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-15T00:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-15T00:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/merck-is-paying-588m-for-potential-successor-to-cancer-drug-juggernaut-keytruda 2024-11-15T00:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-is-paying-588m-for-potential-successor-to-cancer-drug-juggernaut-keytruda 2024-11-15T00:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/could-ozempic-help-treat-substance-use-disorder-women-s-health 2024-11-15T00:12:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-ozempic-help-treat-substance-use-disorder-women-s-health 2024-11-15T00:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-revuforj-revumenib-for-the-treatment-of-adult-and-pediatric-patients-with-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T00:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-revuforj-revumenib-for-the-treatment-of-adult-and-pediatric-patients-with-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T00:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-launches-search-for-150000-volunteers-to-help-transform-cancer-treatment 2024-11-15T00:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-launches-search-for-150000-volunteers-to-help-transform-cancer-treatment 2024-11-15T00:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-study-of-bat4406f-shows-promise-for-nmosd-treatment 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-study-of-bat4406f-shows-promise-for-nmosd-treatment 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/va-launches-progress-study-to-enhance-prostate-cancer-screening-with-genetic-testing 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/va-launches-progress-study-to-enhance-prostate-cancer-screening-with-genetic-testing 2024-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-zolbetuximab-for-cldn18-2-her2-negative-gastric-and-gej 2024-11-14T23:16:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-insights-zolbetuximab-for-cldn18-2-her2-negative-gastric-and-gej 2024-11-14T23:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-bimzelx-r-bimekizumab-bkzx-data-at-acr-convergence-2024-highlights-ucb 2024-11-14T23:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-bimzelx-r-bimekizumab-bkzx-data-at-acr-convergence-2024-highlights-ucb 2024-11-14T23:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nilotinib-tablets-without-mealtime-restrictions-for-cml-onclive 2024-11-14T22:56:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nilotinib-tablets-without-mealtime-restrictions-for-cml-onclive 2024-11-14T22:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-danziten-for-chronic-myeloid-leukemia-without-mealtime-restrictions 2024-11-14T22:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-danziten-for-chronic-myeloid-leukemia-without-mealtime-restrictions 2024-11-14T22:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/vivolta-partners-with-neurochase-to-manufacture-electrospun-microcatheters-for-delivery-of 2024-11-14T22:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivolta-partners-with-neurochase-to-manufacture-electrospun-microcatheters-for-delivery-of 2024-11-14T22:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-wins-first-fda-approval-for-a-gene-therapy-dosed-directly-into-the-brain 2024-11-14T22:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-wins-first-fda-approval-for-a-gene-therapy-dosed-directly-into-the-brain 2024-11-14T22:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/larger-study-supports-safety-of-tetracyclines-during-early-pregnancy-medpage-today 2024-11-14T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larger-study-supports-safety-of-tetracyclines-during-early-pregnancy-medpage-today 2024-11-14T22:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/drug-being-tested-to-address-side-effects-of-cancer-treatment-nebraska-medicine 2024-11-14T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-being-tested-to-address-side-effects-of-cancer-treatment-nebraska-medicine 2024-11-14T22:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/osteal-therapeutics-announces-positive-12-month-results-from-the-apex-clinical-trial 2024-11-14T22:20:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osteal-therapeutics-announces-positive-12-month-results-from-the-apex-clinical-trial 2024-11-14T22:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-demonstrates-significant-benefits-for-patients-with-pre-diabetes-obesity-over 2024-11-14T22:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-demonstrates-significant-benefits-for-patients-with-pre-diabetes-obesity-over 2024-11-14T22:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/world-diabetes-day-2024-looking-back-at-progress-for-cell-and-gene-therapy-cgtlive-r 2024-11-14T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-diabetes-day-2024-looking-back-at-progress-for-cell-and-gene-therapy-cgtlive-r 2024-11-14T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/nilotinib-tablets-approved-by-fda-for-ph-cml-in-chronic-phase-cancer-network 2024-11-14T21:59:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nilotinib-tablets-approved-by-fda-for-ph-cml-in-chronic-phase-cancer-network 2024-11-14T21:59:42+00:00 weekly 0.7 https://trial.medpath.com/news/panbela-provides-business-update-and-reports-q3-2024-financial-results 2024-11-14T21:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/panbela-provides-business-update-and-reports-q3-2024-financial-results 2024-11-14T21:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:57:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fortress-biotech-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-morningstar 2024-11-14T21:57:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-morningstar 2024-11-14T21:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-to-present-new-prespecified-subgroup-analyses-from-investigational-phase-iii 2024-11-14T21:55:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-to-present-new-prespecified-subgroup-analyses-from-investigational-phase-iii 2024-11-14T21:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-medtech-advances-into-surgical-robotics-with-ottava-clinical-trials-zenopa 2024-11-14T21:53:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-medtech-advances-into-surgical-robotics-with-ottava-clinical-trials-zenopa 2024-11-14T21:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/2024-updates-in-gi-cancer-feature-flot-combinations-restricted-fda-approvals-by-pd 2024-11-14T21:49:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-updates-in-gi-cancer-feature-flot-combinations-restricted-fda-approvals-by-pd 2024-11-14T21:49:58+00:00 weekly 0.7 https://trial.medpath.com/news/osteal-therapeutics-announces-positive-12-month-results-globenewswire 2024-11-14T21:49:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osteal-therapeutics-announces-positive-12-month-results-globenewswire 2024-11-14T21:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-gene-therapy-for-rare-neurometabolic-disorder-healio 2024-11-14T21:41:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novel-gene-therapy-for-rare-neurometabolic-disorder-healio 2024-11-14T21:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-first-patient-dosed-in-iggenix-accelerate-peanut-phase-1-clinical-trial-healio 2024-11-14T21:41:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-first-patient-dosed-in-iggenix-accelerate-peanut-phase-1-clinical-trial-healio 2024-11-14T21:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-wins-over-european-regulators-on-alzheimer-s-drug-leqembi-biopharma-dive 2024-11-14T21:41:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-wins-over-european-regulators-on-alzheimer-s-drug-leqembi-biopharma-dive 2024-11-14T21:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-stock-titan 2024-11-14T21:39:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precigen-reports-third-quarter-2024-financial-results-and-business-updates-stock-titan 2024-11-14T21:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/genelux-corporation-reports-third-quarter-2024-financial-globenewswire 2024-11-14T21:27:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genelux-corporation-reports-third-quarter-2024-financial-globenewswire 2024-11-14T21:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/ticker-biogen-alzheimer-s-drug-gets-second-look-in-eu-ford-takes-165m-hit-on-slow-recall 2024-11-14T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ticker-biogen-alzheimer-s-drug-gets-second-look-in-eu-ford-takes-165m-hit-on-slow-recall 2024-11-14T21:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating 2024-11-14T21:18:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enlivex-announces-the-dosing-of-the-first-patient-in-a-phase-i-clinical-trial-evaluating 2024-11-14T21:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024-stock-titan 2024-11-14T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024-stock-titan 2024-11-14T21:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/crinetics-unveils-breakthrough-cancer-drug-platform-reports-positive-phase-2-trial-results 2024-11-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crinetics-unveils-breakthrough-cancer-drug-platform-reports-positive-phase-2-trial-results 2024-11-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-reports-third-quarter-2024-financial-results-and-provides-company-update 2024-11-14T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dare-bioscience-reports-third-quarter-2024-financial-results-and-provides-company-update 2024-11-14T21:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024 2024-11-14T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024 2024-11-14T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-nasdaq-nrxp-reports-third-quarter-and-year-to-date-2024 2024-11-14T21:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/mirdametinib-yields-significant-responses-and-hrqol-improvements-in-nf1-pn 2024-11-14T21:04:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirdametinib-yields-significant-responses-and-hrqol-improvements-in-nf1-pn 2024-11-14T21:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-sought-for-dato-dxd-in-egfr-mutated-nsclc-targeted-oncology 2024-11-14T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-sought-for-dato-dxd-in-egfr-mutated-nsclc-targeted-oncology 2024-11-14T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of 2024-11-14T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of 2024-11-14T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-danziten 2024-11-14T21:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy-yahoo-finance 2024-11-14T20:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy-yahoo-finance 2024-11-14T20:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-14T20:53:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-receives-positive-opinion-from-the-chmp-in-the-european-union-for-lecanemab-in 2024-11-14T20:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-fda-approves-car-t-therapy-for-r-r-b-all-regmednet 2024-11-14T20:41:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-fda-approves-car-t-therapy-for-r-r-b-all-regmednet 2024-11-14T20:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-tirumotecan-shows-antitumor-activity-in-previously-treated-endometrial-onclive 2024-11-14T20:14:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-tirumotecan-shows-antitumor-activity-in-previously-treated-endometrial-onclive 2024-11-14T20:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-prevents-type-2-diabetes-in-99-of-prediabetic-patients-for-3-years 2024-11-14T20:11:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-prevents-type-2-diabetes-in-99-of-prediabetic-patients-for-3-years 2024-11-14T20:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-3-trial-of-amezalpat-in-advanced-liver-cancer-receives-study-may-proceed-letter 2024-11-14T20:08:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-3-trial-of-amezalpat-in-advanced-liver-cancer-receives-study-may-proceed-letter 2024-11-14T20:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-outlines-informed-consent-best-practices-jd-supra 2024-11-14T19:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisory-committee-outlines-informed-consent-best-practices-jd-supra 2024-11-14T19:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-breakthrough-revolutionizing-postpartum-depression-walb 2024-11-14T19:58:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-breakthrough-revolutionizing-postpartum-depression-walb 2024-11-14T19:58:27+00:00 weekly 0.7 https://trial.medpath.com/news/recommendations-for-detection-assessment-and-management-of-suspected-drug-induced 2024-11-14T19:50:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recommendations-for-detection-assessment-and-management-of-suspected-drug-induced 2024-11-14T19:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-secures-ema-thumbs-up-for-narrower-indication 2024-11-14T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqembi-secures-ema-thumbs-up-for-narrower-indication 2024-11-14T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-barron-s 2024-11-14T19:46:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-watchdog-partially-approves-new-alzheimer-s-drug-barron-s 2024-11-14T19:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-speaks-out-about-bone-density-concerns-with-obesity-drug-clinical-trials-arena 2024-11-14T19:43:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-speaks-out-about-bone-density-concerns-with-obesity-drug-clinical-trials-arena 2024-11-14T19:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-r-acute 2024-11-14T19:43:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-r-acute 2024-11-14T19:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/european-committee-takes-a-second-look-at-alzheimer-s-drug-and-now-says-it-should-be-approved 2024-11-14T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-committee-takes-a-second-look-at-alzheimer-s-drug-and-now-says-it-should-be-approved 2024-11-14T19:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-ceo-dr-raza-bokhari-on-4m-nasdaq-ipo-phase-2-trial 2024-11-14T19:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicus-pharma-ceo-dr-raza-bokhari-on-4m-nasdaq-ipo-phase-2-trial 2024-11-14T19:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with 2024-11-14T19:13:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-conditional-approval-for-ptc-therapeutics-gene-therapy-as-first-ever-with 2024-11-14T19:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-enhances-responses-is-well-tolerated-in-hodgkin-lymphoma 2024-11-14T19:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-chemotherapy-enhances-responses-is-well-tolerated-in-hodgkin-lymphoma 2024-11-14T19:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/everything-you-need-to-know-about-nice-s-decisions-on-game-changing-alzheimer-s-drugs 2024-11-14T19:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everything-you-need-to-know-about-nice-s-decisions-on-game-changing-alzheimer-s-drugs 2024-11-14T19:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-kebilidi-as-first-gene-therapy-to-treat-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-14T19:01:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-kebilidi-as-first-gene-therapy-to-treat-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-14T19:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/european-watchdog-partially-approves-new-alzheimer-s-drug-ndtv 2024-11-14T18:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-watchdog-partially-approves-new-alzheimer-s-drug-ndtv 2024-11-14T18:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-s-alzheimer-s-drug-lecanemab-wins-key-eu-panel-backing-after-appeal 2024-11-14T18:40:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-biogen-s-alzheimer-s-drug-lecanemab-wins-key-eu-panel-backing-after-appeal 2024-11-14T18:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/ema-rethinks-stance-committee-now-recommends-leqembi-for-alzheimer-s-disease 2024-11-14T18:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-rethinks-stance-committee-now-recommends-leqembi-for-alzheimer-s-disease 2024-11-14T18:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development 2024-11-14T18:37:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development 2024-11-14T18:37:36+00:00 weekly 0.7 https://trial.medpath.com/news/eu-reverses-course-approval-for-breakthrough-alzheimer-s-drug-leqembi-recommended 2024-11-14T18:31:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-reverses-course-approval-for-breakthrough-alzheimer-s-drug-leqembi-recommended 2024-11-14T18:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-and-avd-the-new-standard-in-hodgkin-lymphoma-national-cancer-institute 2024-11-14T18:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-and-avd-the-new-standard-in-hodgkin-lymphoma-national-cancer-institute 2024-11-14T18:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-posts-second-quarter-loss-widens-as-clinical-trials-advance-green-market-report 2024-11-14T17:55:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-posts-second-quarter-loss-widens-as-clinical-trials-advance-green-market-report 2024-11-14T17:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-provides-clinical-programs-update-marketscreener 2024-11-14T17:44:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corporation-provides-clinical-programs-update-marketscreener 2024-11-14T17:44:09+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-markets-data 2024-11-14T17:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-markets-data 2024-11-14T17:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/kebilidi-aadc-deficiency-gene-therapy-now-approved-by-fda 2024-11-14T17:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kebilidi-aadc-deficiency-gene-therapy-now-approved-by-fda 2024-11-14T17:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-sarclisa-recommended-for-eu-approval-marketscreener 2024-11-14T17:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-s-sarclisa-recommended-for-eu-approval-marketscreener 2024-11-14T17:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T17:35:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T17:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-sarclisa-recommended-for-eu-approval-morningstar 2024-11-14T17:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-s-sarclisa-recommended-for-eu-approval-morningstar 2024-11-14T17:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/wet-amd-therapeutics-technologies-raising-the-ceiling-for-functional-visual-outcomes 2024-11-14T17:24:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wet-amd-therapeutics-technologies-raising-the-ceiling-for-functional-visual-outcomes 2024-11-14T17:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-lowers-type-2-diabetes-risk-in-phase-3-trial-study-becker-s-hospital-review 2024-11-14T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mounjaro-lowers-type-2-diabetes-risk-in-phase-3-trial-study-becker-s-hospital-review 2024-11-14T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant 2024-11-14T17:18:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sarclisa-recommended-for-eu-approval-by-the-chmp-to-treat-transplant 2024-11-14T17:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-markets-data 2024-11-14T17:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-markets-data 2024-11-14T17:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/eftilagimod-alpha-plus-pembrolizumab-chemo-generates-improved-survival-trends-in 2024-11-14T17:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eftilagimod-alpha-plus-pembrolizumab-chemo-generates-improved-survival-trends-in 2024-11-14T17:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-polypid-reports-on-d-plex100-trial-and-financials-investing-com-uk 2024-11-14T17:17:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-polypid-reports-on-d-plex100-trial-and-financials-investing-com-uk 2024-11-14T17:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-stock-titan 2024-11-14T17:17:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-stock-titan 2024-11-14T17:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/eu-backs-eisai-alzheimer-s-drug-in-reversal-of-earlier-rejection-bnn-bloomberg 2024-11-14T17:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-backs-eisai-alzheimer-s-drug-in-reversal-of-earlier-rejection-bnn-bloomberg 2024-11-14T17:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/eu-backs-leqembi-a-breakthrough-in-alzheimer-s-treatment-health-devdiscourse 2024-11-14T17:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-backs-leqembi-a-breakthrough-in-alzheimer-s-treatment-health-devdiscourse 2024-11-14T17:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-prevention-trial-receives-74-5-million-nih-grant 2024-11-14T17:11:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-prevention-trial-receives-74-5-million-nih-grant 2024-11-14T17:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-pr-newswire 2024-11-14T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu-pr-newswire 2024-11-14T17:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-icobrain-aria-first-ai-tool-for-safer-aria-detection-in-alzheimer-treatment 2024-11-14T17:05:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-icobrain-aria-first-ai-tool-for-safer-aria-detection-in-alzheimer-treatment 2024-11-14T17:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial 2024-11-14T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial 2024-11-14T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/tau-modification-drugs-take-a-hit-with-negative-trial-alzforum 2024-11-14T16:56:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tau-modification-drugs-take-a-hit-with-negative-trial-alzforum 2024-11-14T16:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-weakness-in-drug-resistant-tuberculosis-pathogens-news-medical 2024-11-14T16:47:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-weakness-in-drug-resistant-tuberculosis-pathogens-news-medical 2024-11-14T16:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-wins-us-approval-of-gene-therapy-for-fatal-enzyme-disorder-biopharma-dive 2024-11-14T16:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-wins-us-approval-of-gene-therapy-for-fatal-enzyme-disorder-biopharma-dive 2024-11-14T16:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-breast-cancer-after-care-better-care-programme-to-improve-breast-cancer-follow-up 2024-11-14T16:47:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-breast-cancer-after-care-better-care-programme-to-improve-breast-cancer-follow-up 2024-11-14T16:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sarclisa-recommended-for-eu-approval-by-the-globenewswire 2024-11-14T16:45:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sarclisa-recommended-for-eu-approval-by-the-globenewswire 2024-11-14T16:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/microbion-reports-topline-data-from-phase-ii-study-of-dfi-therapy-clinical-trials-arena 2024-11-14T16:45:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbion-reports-topline-data-from-phase-ii-study-of-dfi-therapy-clinical-trials-arena 2024-11-14T16:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-formation-and-openai-design-ai-tool-to-slash-clinical-trial-timelines-oodaloop 2024-11-14T16:35:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-formation-and-openai-design-ai-tool-to-slash-clinical-trial-timelines-oodaloop 2024-11-14T16:35:30+00:00 weekly 0.7 https://trial.medpath.com/news/are-glp-1-drugs-really-for-everybody-nature-medicine 2024-11-14T16:29:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-glp-1-drugs-really-for-everybody-nature-medicine 2024-11-14T16:29:22+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu 2024-11-14T16:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-recommendation-for-approval-of-lecanemab-in-the-eu 2024-11-14T16:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-breakthrough-device-decisions-rebound-after-recent-declines-medtech-dive 2024-11-14T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-breakthrough-device-decisions-rebound-after-recent-declines-medtech-dive 2024-11-14T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial-clinical-trials-arena 2024-11-14T16:14:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-wins-fda-breakthrough-status-enrols-first-patient-in-pivotal-trial-clinical-trials-arena 2024-11-14T16:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints 2024-11-14T16:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-nets-aadc-gene-therapy-approval-first-brain-delivered-gene-therapy-in-u-s 2024-11-14T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-nets-aadc-gene-therapy-approval-first-brain-delivered-gene-therapy-in-u-s 2024-11-14T15:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-morningstar 2024-11-14T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-presents-positive-phase-ii-data-for-novel-neurotrophin-3-inhibitor-levi-04-morningstar 2024-11-14T15:53:18+00:00 weekly 0.7 https://trial.medpath.com/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-of-biospace 2024-11-14T15:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-of-biospace 2024-11-14T15:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/new-weight-loss-drug-cuts-appetite-without-causing-muscle-loss-study-finds 2024-11-14T15:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-weight-loss-drug-cuts-appetite-without-causing-muscle-loss-study-finds 2024-11-14T15:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/reach-completes-phase-ii-of-future-force-energy-campaign-with-u-s-air-force-morningstar 2024-11-14T15:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reach-completes-phase-ii-of-future-force-energy-campaign-with-u-s-air-force-morningstar 2024-11-14T15:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-cancer-biomarkers-promise-improved-survival-inside-precision-medicine 2024-11-14T15:38:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bladder-cancer-biomarkers-promise-improved-survival-inside-precision-medicine 2024-11-14T15:38:31+00:00 weekly 0.7 https://trial.medpath.com/news/nrxbf-gains-another-governmental-designation-zacks-small-cap-research 2024-11-14T15:36:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrxbf-gains-another-governmental-designation-zacks-small-cap-research 2024-11-14T15:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-gene-therapy-to-treat-aadc-deficiency 2024-11-14T15:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-gene-therapy-to-treat-aadc-deficiency 2024-11-14T15:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-reports-trial-results-of-tirzepatide-for-treating-obesity-and-pre-diabetes 2024-11-14T15:31:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-reports-trial-results-of-tirzepatide-for-treating-obesity-and-pre-diabetes 2024-11-14T15:31:33+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-breast-imaging-reduces-need-for-axillary-lymph-node-dissection-in-breast-cancer 2024-11-14T15:30:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-breast-imaging-reduces-need-for-axillary-lymph-node-dissection-in-breast-cancer 2024-11-14T15:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on 2024-11-14T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-egfr-inhibition-marks-transformative-era-in-lung-cancer-treatment 2024-11-14T15:25:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolution-of-egfr-inhibition-marks-transformative-era-in-lung-cancer-treatment 2024-11-14T15:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/in-case-you-missed-it-roundup-from-esmo-congress-2024-the-asco-post 2024-11-14T15:21:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-case-you-missed-it-roundup-from-esmo-congress-2024-the-asco-post 2024-11-14T15:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-gene-therapy-for-debilitating-enzyme-deficiency 2024-11-14T15:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-gene-therapy-for-debilitating-enzyme-deficiency 2024-11-14T15:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-presents-positive-phase-ii-data-for-novel-globenewswire 2024-11-14T15:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-presents-positive-phase-ii-data-for-novel-globenewswire 2024-11-14T15:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/nipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg 2024-11-14T15:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg 2024-11-14T15:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gains-buy-rating-following-fda-approval-of-groundbreaking-gene 2024-11-14T15:13:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-gains-buy-rating-following-fda-approval-of-groundbreaking-gene 2024-11-14T15:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-clinical-trial-of-ata-200-gene-therapy-for-lgmd-children 2024-11-14T15:10:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-clinical-trial-of-ata-200-gene-therapy-for-lgmd-children 2024-11-14T15:10:55+00:00 weekly 0.7 https://trial.medpath.com/news/review-approving-using-jak-inhibitors-for-better-alopecia-areata-outcomes 2024-11-14T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-approving-using-jak-inhibitors-for-better-alopecia-areata-outcomes 2024-11-14T15:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-14T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-14T15:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-combination-shows-promise-in-metastatic-kidney-cancer-medpage-today 2024-11-14T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-combination-shows-promise-in-metastatic-kidney-cancer-medpage-today 2024-11-14T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-positive-results-for-potential-treatment-to-combat-a-challenging-rare-disease 2024-11-14T15:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-shows-positive-results-for-potential-treatment-to-combat-a-challenging-rare-disease 2024-11-14T15:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drug-rejections-have-one-fatal-flaw-realclearhealth 2024-11-14T15:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-drug-rejections-have-one-fatal-flaw-realclearhealth 2024-11-14T15:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-outlines-new-strategy-amid-tecelra-launch 2024-11-14T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptimmune-outlines-new-strategy-amid-tecelra-launch 2024-11-14T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-eladocagene-exuparvovec-tneq-for-treatment-of-aadc-deficiency 2024-11-14T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-eladocagene-exuparvovec-tneq-for-treatment-of-aadc-deficiency 2024-11-14T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/leqembi-side-effects-no-worse-in-clinical-use-than-they-were-in-trial-alzforum 2024-11-14T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqembi-side-effects-no-worse-in-clinical-use-than-they-were-in-trial-alzforum 2024-11-14T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-single-crispr-treatment-could-replace-a-lifetime-of-daily-treatment-in-hereditary-angioedema 2024-11-14T14:50:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-single-crispr-treatment-could-replace-a-lifetime-of-daily-treatment-in-hereditary-angioedema 2024-11-14T14:50:03+00:00 weekly 0.7 https://trial.medpath.com/news/widely-integrated-services-in-home-wish-for-homebound-older-adults-a-study-protocol-for 2024-11-14T14:36:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/widely-integrated-services-in-home-wish-for-homebound-older-adults-a-study-protocol-for 2024-11-14T14:36:57+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-ii-top-line-data-highlights-omadacycline-s-potential-in-the-ntm-market 2024-11-14T14:36:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-ii-top-line-data-highlights-omadacycline-s-potential-in-the-ntm-market 2024-11-14T14:36:15+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-globenewswire 2024-11-14T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-globenewswire 2024-11-14T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candel-therapeutics-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-inc-sec-10-q-report-tradingview 2024-11-14T14:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy 2024-11-14T14:21:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-ptc-s-aadc-deficiency-gene-therapy 2024-11-14T14:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-reports-data-from-phase-iii-trial-of-aml-treatment-msn 2024-11-14T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-reports-data-from-phase-iii-trial-of-aml-treatment-msn 2024-11-14T14:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:07:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mabwell-s-novel-nectin-4-targeting-adc-9mw2821-approved-for-2-clinical-trials-by-cde-of-nmpa 2024-11-14T14:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-looks-at-why-cancer-treatments-cause-heart-damage-uc-san-francisco 2024-11-14T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-looks-at-why-cancer-treatments-cause-heart-damage-uc-san-francisco 2024-11-14T14:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/malaria-developing-resistance-to-drug-that-saves-children-s-lives 2024-11-14T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/malaria-developing-resistance-to-drug-that-saves-children-s-lives 2024-11-14T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corp-reports-q3-2024-gaap-eps-of-0-29-missi-gurufocus 2024-11-14T13:55:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corp-reports-q3-2024-gaap-eps-of-0-29-missi-gurufocus 2024-11-14T13:55:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-car-t-therapy-for-adults-with-acute-leukemia-cancer-health 2024-11-14T13:54:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-car-t-therapy-for-adults-with-acute-leukemia-cancer-health 2024-11-14T13:54:26+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-reports-third-quarter-2024-results-and-other-exciting-events 2024-11-14T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-reports-third-quarter-2024-results-and-other-exciting-events 2024-11-14T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/medistim-launches-clinical-study-on-ttfm-and-hfus-in-vascular-surgery-finansavisen 2024-11-14T13:47:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medistim-launches-clinical-study-on-ttfm-and-hfus-in-vascular-surgery-finansavisen 2024-11-14T13:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/missing-outcome-data-in-randomised-clinical-trials-of-psychological-interventions-bmc-psychiatry 2024-11-14T13:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/missing-outcome-data-in-randomised-clinical-trials-of-psychological-interventions-bmc-psychiatry 2024-11-14T13:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/chemomab-therapeutics-announces-third-quarter-2024-financial-results-and-provides 2024-11-14T13:39:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemomab-therapeutics-announces-third-quarter-2024-financial-results-and-provides 2024-11-14T13:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-defends-obesity-drug-amid-bone-concerns-stat-news 2024-11-14T13:38:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-defends-obesity-drug-amid-bone-concerns-stat-news 2024-11-14T13:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/calidi-biotherapeutics-raises-7-5m-in-public-offering-for-clinical-trials-cldi-stock-news 2024-11-14T13:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calidi-biotherapeutics-raises-7-5m-in-public-offering-for-clinical-trials-cldi-stock-news 2024-11-14T13:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-pr-newswire 2024-11-14T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-pr-newswire 2024-11-14T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-yahoo-finance 2024-11-14T13:21:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-accelerates-planned-unblinded-data-readout-for-miracle-phase-3-r-yahoo-finance 2024-11-14T13:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-biotech-provides-clinical-programs-update-and-reports-third-quarter 2024-11-14T13:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-biotech-provides-clinical-programs-update-and-reports-third-quarter 2024-11-14T13:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-accelerates-phase-3-aml-trial-data-timeline-to-h2-2025-mbrx-stock-news 2024-11-14T13:19:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-biotech-accelerates-phase-3-aml-trial-data-timeline-to-h2-2025-mbrx-stock-news 2024-11-14T13:19:18+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-s-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer 2024-11-14T13:18:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-s-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer 2024-11-14T13:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T13:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting 2024-11-14T13:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-gets-fda-nod-for-kebilidi-to-treat-aadc-deficiency 2024-11-14T13:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-gets-fda-nod-for-kebilidi-to-treat-aadc-deficiency 2024-11-14T13:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-14T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-yahoo-finance 2024-11-14T13:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-yahoo-finance 2024-11-14T13:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-expanded-age-indication-for-nerivio-migraine-device-in-pediatric-patients 2024-11-14T13:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-expanded-age-indication-for-nerivio-migraine-device-in-pediatric-patients 2024-11-14T13:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T13:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candel-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights 2024-11-14T13:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-s-denifanstat-earns-fda-breakthrough-status-reports-170m-cash-position 2024-11-14T13:01:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-s-denifanstat-earns-fda-breakthrough-status-reports-170m-cash-position 2024-11-14T13:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-wins-first-fda-nod-for-direct-to-brain-gene-therapy-targets-ultrarare-disease 2024-11-14T12:56:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-wins-first-fda-nod-for-direct-to-brain-gene-therapy-targets-ultrarare-disease 2024-11-14T12:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-pr-newswire 2024-11-14T12:44:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-pr-newswire 2024-11-14T12:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-morningstar 2024-11-14T12:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/khondrion-receives-fda-clearance-of-ind-application-for-pivotal-phase-3-clinical-trial-morningstar 2024-11-14T12:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-stock-titan 2024-11-14T12:40:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-reports-first-quarter-fiscal-year-2025-operating-financial-results-stock-titan 2024-11-14T12:40:01+00:00 weekly 0.7 https://trial.medpath.com/news/merck-kgaa-abbisko-share-positive-phase-3-results-for-pimicotinib-in-rare-tumour-type 2024-11-14T12:35:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-kgaa-abbisko-share-positive-phase-3-results-for-pimicotinib-in-rare-tumour-type 2024-11-14T12:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-gears-up-for-fda-approval-of-fingerprint-drug-detection-device-yahoo-finance 2024-11-14T12:21:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intelligent-gears-up-for-fda-approval-of-fingerprint-drug-detection-device-yahoo-finance 2024-11-14T12:21:35+00:00 weekly 0.7 https://trial.medpath.com/news/cabaletta-bio-expands-clinical-trials-to-40-sites-reports-183m-cash-position-caba-stock-news 2024-11-14T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabaletta-bio-expands-clinical-trials-to-40-sites-reports-183m-cash-position-caba-stock-news 2024-11-14T12:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/appili-therapeutics-reports-fda-approved-drug-launch-advances-vaccine-pipeline-in-q2 2024-11-14T12:18:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/appili-therapeutics-reports-fda-approved-drug-launch-advances-vaccine-pipeline-in-q2 2024-11-14T12:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-abeona-therapeutics-bla-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-11-14T12:17:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-abeona-therapeutics-bla-for-epidermolysis-bullosa-gene-therapy-pz-cel 2024-11-14T12:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results 2024-11-14T12:15:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protalix-biotherapeutics-reports-third-quarter-2024-financial-and-business-results 2024-11-14T12:15:41+00:00 weekly 0.7